National Cancer Institute Seeks Pharmaceutical Company for Homoharringtonine Cancer Treatment

Summary

The National Cancer Institute is seeking a pharmaceutical company to collaborate on the clinical development of Homoharringtonine, a potential anticancer agent, in exchange for a Cooperative Research and Development Agreement (CRADA) that could last 3 to 5 years.